No matches
Type 2 Inflammation

Multifaceted Role of IL-13 in Airway Remodeling

Join Dr. Celeste Porsbjerg as she discusses on how IL-13 contributes to mucus plugging in asthma.
Celeste Porsbjerg
MD, PhD
Celeste Porsbjerg

Learning objectives

  • To assess impact of IL-13 on Mucus Production and Clearance
  • To assess the role of IL-13 in airway remodeling

Description

In this video clip,  from the ERS 2024 symposium, Dr. Celeste Porsbjerg delves into the role of IL-13 in asthma pathophysiology, highlighting how IL-13 contributes to mucus overproduction, impairs mucociliary clearance, and leads to airway wall thickening and tissue fibrosis. 

Tags
IL-13mucusasthma
MAT-GLB-2503459 - 1.0 - 07/2025

About this expert

Pulmonology

Celeste Porsbjerg

MD, PhD

Professor of Severe Asthma, Bispebjerg Hospital Copenhagen, Denmark

See author’s profile
Celeste Porsbjerg

Related resources

Multidisciplinary Partnership for Type 2 Inflammatory Diseases
Type 2 Inflammation
expert video

Multidisciplinary Partnership for Type 2 Inflammatory Diseases

Type 2 Inflammation Underpins Pediatric Severe Asthma
Pulmonology
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD
Type 2 Inflammation
expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

Importance of Lung Function Assessment in Pediatric Asthma Patients
Pulmonology
videoanimation

Importance of Lung Function Assessment in Pediatric Asthma Patients

Role of Type 2 Inflammation Across Different Chronic Diseases
Type 2 Inflammation
expert video

Role of Type 2 Inflammation Across Different Chronic Diseases

Trajectories of Type 2 Inflammation in Pediatric Patients
Type 2 Inflammation
expert video

Trajectories of Type 2 Inflammation in Pediatric Patients

Evolving Topics in Type 2 Inflammation
Type 2 Inflammation
expert video

Evolving Topics in Type 2 Inflammation

Connecting the Dots from Type 2 Inflammation to Patient Perspectives
Type 2 Inflammation
expert video

Connecting the Dots from Type 2 Inflammation to Patient Perspectives

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission
Pulmonology
expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma
Pulmonology
Podcast

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Eosinophils as a Biomarker for Type 2 Asthma
Pulmonology
expert video

Eosinophils as a Biomarker for Type 2 Asthma

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
Pulmonology
expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Burdens Experienced by Pediatric Asthma Patients and Their Caregivers
Pulmonology
expert video

Burdens Experienced by Pediatric Asthma Patients and Their Caregivers

Concerns Surrounding OCS Side Effects in Patients With Severe Asthma
Pulmonology
expert video

Concerns Surrounding OCS Side Effects in Patients With Severe Asthma

Expert Insights: Importance of Lung Function Assessment in Pediatric Asthma Patients
Pulmonology
expert video

Expert Insights: Importance of Lung Function Assessment in Pediatric Asthma Patients

FeNO as a Biomarker for Type 2 Asthma
Pulmonology
expert video

FeNO as a Biomarker for Type 2 Asthma

How Can FeNO Support the Management of Pediatric Asthma?
Pulmonology
expert video

How Can FeNO Support the Management of Pediatric Asthma?

IgE as a Biomarker for Type 2 Asthma
Pulmonology
expert video

IgE as a Biomarker for Type 2 Asthma

Importance of Lung Function Assessment in Adult Asthma Patients
Pulmonology
videoanimation

Importance of Lung Function Assessment in Adult Asthma Patients

On-Treatment Clinical Remission in Asthma Patients Case Tool
Pulmonology
interactivity

On-Treatment Clinical Remission in Asthma Patients Case Tool

The Cycle of Inflammation in Adult Asthma
Pulmonology
interactivity

The Cycle of Inflammation in Adult Asthma

What Differentiates COPD Exacerbations From Asthma Exacerbations?
Pulmonology
expert video

What Differentiates COPD Exacerbations From Asthma Exacerbations?

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis
Type 2 Inflammation
expert video

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

Clinical Manifestations Associated With Airway Remodeling in Asthma
Type 2 Inflammation
expert video

Clinical Manifestations Associated With Airway Remodeling in Asthma

Impact of Exacerbations in COPD
Type 2 Inflammation
expert video

Impact of Exacerbations in COPD

Exacerbations Lead to Worsening Lung Function
Type 2 Inflammation
expert video

Exacerbations Lead to Worsening Lung Function

Type 2 Inflammation Digital Assessment Tool
Pulmonology
interactivity

Type 2 Inflammation Digital Assessment Tool

2025 ADVENT Pulmonology/Rhinology Forum | Joint Plenary Session: A View into the Life of Our Patients Video
Type 2 Inflammation
expert video

2025 ADVENT Pulmonology/Rhinology Forum | Joint Plenary Session: A View into the Life of Our Patients Video

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma
Type 2 Inflammation
expert video

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Mucus Plugging as a Potential Target in Asthma Management
Type 2 Inflammation
expert video

Mucus Plugging as a Potential Target in Asthma Management

Multifaceted Role of IL-13 in Airway Remodeling
Type 2 Inflammation
expert video

Multifaceted Role of IL-13 in Airway Remodeling

Pediatric Asthma Trajectory and Clinical Remission
Type 2 Inflammation
expert video

Pediatric Asthma Trajectory and Clinical Remission

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region